Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $4.51M | $2.30M | $3.94M | $297K | $0.00 | $2.00M | $2.07M |
| Revenue growth | — | — | -49.1% | 71.7% | -92.5% | -100.0% | — | 3.7% |
| Operating income | -$115M | -$125M | -$81.3M | -$55.2M | -$18.5M | -$13.0M | -$3.63M | -$4.97M |
| Operating margin | — | -2774.3% | -3539.4% | -1400.2% | -6242.4% | — | -181.4% | -239.8% |
| Net income | -$115M | -$123M | -$77.8M | -$51.6M | -$44.1M | -$5.26M | -$3.06M | -$3.53M |
| Net margin | — | -2729.3% | -3388.6% | -1310.2% | -14841.1% | — | -152.8% | -170.1% |
| EPS (diluted) | -$4.21 | -$4.49 | -$2.56 | -$1.32 | -$20.28 | -$2.25 | -$1.21 | -$1.11 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$97.5M | -$102M | -$72.5M | -$36.5M | -$40.6M | -$21.2M | -$4.33M | -$3.31M |
| Capital expenditures | $3.44M | $6.89M | $1.52M | $7.00K | $0.00 | — | — | — |
| Free cash flow | -$101M | -$109M | -$74.0M | -$36.5M | -$40.6M | — | — | — |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $0.00 | $94.9M | $54.4M | $54.0M | $13.4M | $7.57M | $3.23M | $3.24M |
| Total assets | $7.40M | $186M | $115M | $59.3M | $18.1M | $13.4M | $9.57M | $9.98M |
| Shareholders' equity | -$10.4M | $97.7M | $59.5M | $48.2M | $10.5M | $11.3M | $8.85M | $9.09M |
| Retained earnings | — | -$85.6M | -$163M | -$215M | -$259M | -$264M | -$267M | -$271M |
| Shares (wtd avg diluted) | — | 27.6M | 34.0M | 39.1M | 2.17M | 2.34M | 2.52M | 3.18M |
Every figure is extracted from Cyclerion Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.